Search
GLB-004
go.drugbank.com/drugs/DB32796ExperimentalGLB-004 is a molecular glue degrader targeting ARNT(HIF-1β).[L56125, L56126]
GLB-005
go.drugbank.com/drugs/DB32797ExperimentalGLB-005 is a molecular glue degrader targeting WIZ and is being investigated for treatment of sickle cell disease and β-thalassemia.[L56125, L56126, L56128]
GLB-007
go.drugbank.com/drugs/DB32798ExperimentalGLB-007 is a molecular glue degrader targeting WIZ and ZBTB7A.[L56125, L56126, L56128]
GLB-006
go.drugbank.com/drugs/DB32799ExperimentalGLB-006 is a molecular glue degrader targeting NEK7.[L56125, L56126]
APT20TTMG
go.drugbank.com/drugs/DB32869ExperimentalAPT20TTMG is a synthetic DNA that modulates U1 small nuclear ribonucleoprotein misassembly.
RS5441
go.drugbank.com/drugs/DB33178ExperimentalRS5441, also known as ET-02, is a small molecule topical medication investigated for male pattern baldness and age-related alopecia.[L57508, L57509]
Gadoquatrane
go.drugbank.com/drugs/DB33282ApprovedGadoquatrane is a macrocyclic gadolinium-based contrast agent used to enhance magnetic resonance imaging. … [L63814] Like other gadolinium agents it is paramagnetic, developing a magnetic moment in the scanner's field that alters the relaxation of nearby water protons and brightens tissues with abnormal vascularity
Cetuximab
go.drugbank.com/drugs/DB00002ApprovedInvestigational[A227963] EGFR is often mutated in certain types of cancer and serves as a driver of tumorigenesis. … Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor